Leerink raised the firm’s price target on Alnylam to $159 from $138 and keeps a Market Perform rating on the shares. Monday’s update was an incremental positive for the transthyretin amyloidosis cardiomyopathy community, and a third treatment could be approvable as a second-line option after stabilizers already approved, the analyst tells investors in a research note. Leerink believes full data at European Society of Cardiology Congress, in line with yesterday’s top line at the disclosed timepoints, would likely be approvable.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Alnylam (NASDAQ:ALNY) Soars on Positive Topline Results for Vutrisiran
- Alnylam reports results from its HELIOS-B Phase 3 study of vutrisiran
- Ionis Pharmaceuticals upgraded to Market Perform from Underperform at Bernstein
- Citi opens ‘positive catalyst watch’ on Alnylam in data readout
- Alnylam price target raised to $400 from $395 at H.C. Wainwright